Takeda Pharmaceutical Co Ltd (TKPHF) — SEC Filings
Takeda Pharmaceutical Co Ltd (TKPHF) — 50 SEC filings. Latest: 6-K (Dec 18, 2025). Includes 45 6-K, 5 13F-HR.
View Takeda Pharmaceutical Co Ltd on SEC EDGAR
Overview
Takeda Pharmaceutical Co Ltd (TKPHF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 8, 2025: Takeda Pharmaceutical Company Limited filed a Form 6-K on December 8, 2025, reporting as a foreign private issuer. The filing indicates Takeda will file its annual reports under Form 20-F. No specific financial or operational details beyond the filing type and date were provided in this excerpt.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 50 neutral. The dominant filing sentiment for Takeda Pharmaceutical Co Ltd is neutral.
Filing Type Overview
Takeda Pharmaceutical Co Ltd (TKPHF) has filed 45 6-K, 5 13F-HR with the SEC between Jun 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of TKPHF's 44 recent filings, 0 were flagged as high-risk, 0 as medium-risk, and 44 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Top Tags
foreign-private-issuer (38) · sec-filing (19) · reporting (14) · regulatory-filing (10) · 6-K (10) · 6-k (2) · foreign-issuer (2) · financing (2) · regulatory-update (2) · routine-report (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC File Number | 001-38757 | Identifies Takeda's registration with the SEC. |
| Senior Notes due 2034 | $1.1B | Part of Takeda's debt issuance |
| Senior Notes due 2044 | $800M | Part of Takeda's debt issuance |
| Senior Notes due 2054 | $600M | Part of Takeda's debt issuance |
| Senior Notes due 2064 | $500M | Part of Takeda's debt issuance |
Frequently Asked Questions
What are the latest SEC filings for Takeda Pharmaceutical Co Ltd (TKPHF)?
Takeda Pharmaceutical Co Ltd has 50 recent SEC filings from Jun 2024 to Dec 2025, including 45 6-K, 5 13F-HR. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of TKPHF filings?
Across 50 filings, the sentiment breakdown is: 50 neutral. The dominant sentiment is neutral.
Where can I find Takeda Pharmaceutical Co Ltd SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Takeda Pharmaceutical Co Ltd (TKPHF) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Takeda Pharmaceutical Co Ltd?
Financial highlights for Takeda Pharmaceutical Co Ltd are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for TKPHF?
Investment thesis data for TKPHF will be available once enriched filings are processed.
Who are the key executives at Takeda Pharmaceutical Co Ltd?
Executive information for Takeda Pharmaceutical Co Ltd is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Takeda Pharmaceutical Co Ltd stock?
Of TKPHF's 44 assessed filings, 0 were flagged high-risk, 0 medium-risk, and 44 low-risk.
What are recent predictions and forward guidance from Takeda Pharmaceutical Co Ltd?
Forward guidance and predictions for Takeda Pharmaceutical Co Ltd are extracted from SEC filings as they are enriched.